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Background: Cancer is a multifactorial disease not only restricted to transformed epithelium, but also involving cells of the
immune system and cells of mesenchymal origin, particularly mesenchymal stem cells (MSCs). Mesenchymal stem cells contribute
to blood- and lymph- neoangiogenesis, generate myofibroblasts, with pro-invasive activity and may suppress anti-tumour
immunity.
Methods: In this paper, we evaluated the presence and features of MSCs isolated from human head neck squamous cell
carcinoma (HNSCC).
Results: Fresh specimens of HNSCC showed higher proportions of CD90þ cells compared with normal tissue; these cells
co-expressed CD29, CD105, and CD73, but not CD31, CD45, CD133, and human epithelial antigen similarly to bone marrow-
derived MSCs (BM-MSCs). Adherent stromal cells isolated from tumour shared also differentiation potential with BM-MSCs, thus
we named them as tumour-MSCs. Interestingly, tumour-MSCs showed a clear immunosuppressive activity on in vitro stimulated T
lymphocytes, mainly mediated by indoelamine 2,3 dioxygenase activity, like BM-MSCs. To evaluate their possible role in tumour
growth in vivo, we correlated tumour-MSC proportions with neoplasm size. Tumour-MSCs frequency directly correlated with
tumour volume and inversely with the frequency of tumour-infiltrating leukocytes.
Conclusions: These data support the concept that tumour-MSCs may favour tumour growth not only through their effect on
stromal development, but also by inhibiting the anti-tumour immune response.
It is well established that cancer is not simply a disease confined to
transformed epithelial cells, but it is deeply influenced by the
stromal microenvironment. In this context, immune cells (Finn,
2012) and cells of mesenchymal origin (Bergfeld and DeClerck,
2010) have a major role.
Cells derived by the mesenchymal lineage are responsible for
stromal architecture, blood- and lymph-vessel formation and for
the production of several soluble and surface molecules, including
growth factors, chemokines, and molecules with immunosuppres-
sive activity. In this context, mesenchymal stem cells (MSCs), are
thought to have a pivotal role (Rajantie et al, 2004; Mishra et al,
2008; Spaeth et al, 2009).
MSCs are adherent, multipotent, non-hematopoietic progenitor
cells, initially obtained and characterised from bone marrow (BM)
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samples, which have multilineage differentiation potential into
various tissues of different origin, including adipocytes, osteoblasts,
chondrocytes, tenocytes, skeletal and cardiac myocytes, cells of
visceral mesoderm, and neural cells (Nakahara et al, 1991; Natsu
et al, 2004; Horwitz et al, 2005; Rojas et al, 2005; Gucciardo et al,
2009). MSCs can be obtained from tissues other than BM, such as
fat (Zuk et al, 2002), periodontal ligament (Mitrano et al, 2010),
glomeruli (Bruno et al, 2009), placenta (In’t Anker et al, 2003),
endometrium (Schu¨ring et al, 2011), umbilical cord blood (Bieback
and Kluter, 2007), fetal BM, blood, lung, liver, spleen, and
peripheral blood (PB) (Flynn et al, 2007). As there are no specific
markers for human MSCs, they are recognised on the basis of a
complex immunophenotype, including the lack of hematopoietic
stem cell (i.e., CD45 and CD34) and endothelial cell (i.e., CD31)
markers, and the expression of a number of surface molecules, such
as CD105, CD73, CD106, CD54, CD44, CD90, CD29, and STRO-1
(Horwitz et al, 2005). However, the MSC nature of adherent
stromal-like cells can be confirmed only with functional assays that
show their capacity to undergo multilineage differentiation in vitro
under the effect of specific media (Horwitz et al, 2005).
One of the solid tumours in which a potential negative role of
MSCs has been proposed is the head neck squamous cell
carcinoma (HNSCC) (De Boeck et al, 2010). In particular, an
increasing body of data support the hypothesis that resident and/or
bone marrow-derived MSCs are the precursors of the stromal cell
populations present in solid tumours (Lin et al, 2007; Sun et al,
2011; Xu et al, 2011; Hu et al, 2013). Here these cells contribute to
blood and lymph neoangiogenesis, and generate tumour-associated
myofibroblasts, known to possess pro-invasive activity (De Wever
et al, 2008; De Boeck et al, 2010). More importantly some
researchers, starting from previous data demonstrating the
immunosuppressive activity of MSCs (Bartholomew et al, 2002;
Le Blanc et al, 2004; Krampera et al, 2006; Liotta et al, 2008; Baron
et al, 2010), have proposed that tumour-associated MSC could
modulate the anti-tumour response of the immune system,
favouring tumour growth (De Wever et al, 2008).
Head neck squamous cell carcinoma is the sixth leading cancer
by incidence worldwide, there are about 780 000 new cases per year
all over the world and only 40%–50% of patients with HNSCC will
survive for 5 years (Forastiere et al, 2001). The incidence of this
tumour depends on several factors, including geographic arrange-
ment, indeed, HNSCC reaches the 50% of all of the tumours in
East Asia, vs 5% in Europe and America. Tobacco use is the
principle cause of malignant HNSCC: the risk of developing the
tumour in smokers is three to four times higher than in non-
smokers. The alcohol intake is the second risk factor. Furthermore,
a subgroup of HNSCCs, particularly those of the oropharynx,
seems to be associated with infection with high-risk types of
human papillomavirus (HPV). Human papillomavirus-positive
and HPV-negative tumours represent different clinical–
pathological and molecular entities (Sturgis and Cinciripini,
2007). Despite advances in treatment, which have improved the
quality of life, survival rates are not improved significantly in the
last 30 years. Mortality remains high because of the development of
lymph node and distant metastases, the emergence of therapy
resistance, the occurrence of local and regional recurrences. One
clear indication on the contribution of the immune system in
controlling HNSCC is the relative increase of tumour incidence in
the presence of acquired or iatrogenic immunodeficiency. King
et al (1995). identified premalignant lip leukoplakia in 13% of renal
transplant patients, as compared with 0.6% of control age- and sex-
matched individuals. Of these patients, a majority demonstrated
dysplastic conversion and 10% of them showed the presence of
HNSCC. Many other reports examining databases of transplant
recipients confirmed this increased prevalence of tumour (Harris
and Penn, 1981). In addition, analysis of patients who underwent
bone marrow transplantation for haematologic malignancies also
demonstrated a 17.4-fold increased risk for oral cancer (Baker et al,
2003).
In the present study, we aimed to assess the presence of MSCs in
HNSCC and to evaluate their biologic role with particular regard to
the immune response. As first step, we studied, by flow cytometry,
the cell composition of single-cell suspensions derived from fresh
tumour tissue samples: epithelial elements (HEAþ cells), cells of
stromal origin (CD90þ cells), endothelial cells (CD31þ cells)
and leukocytes (CD45þ cells). Subsequently, we isolated
mesenchymal stromal cells, by selecting adherent cells from
in vitro culture in plastic flasks, accordingly with the recommenda-
tions of the International Society for Cellular Therapy 2005 for the
isolation of MSCs. These cell cultures resulted homogenous for cell
composition in terms of morphology (fibroblast-like shape) and
were absolutely comparable to bone marrow-derived MSCs (BM-
MSCs) in terms of cell phenotype and differentiation potential, so
we will refer to these cells as tumour-derived MSCs (tumour-
MSCs). Moreover, we found that tumour-MSC were able to
abrogate T-cell proliferation in a dose-dependent fashion, mainly
through IDO activity comparably with conventional BM-MSC.
Finally, to evaluate the possible negative in vivo role of tumour-
MSCs, we correlated their frequencies in HNSCC specimens, with
tumour dimension and we observed a direct correlation.
MATERIALS AND METHODS
Subjects. Thirteen patients affected by HNSCC, biopsy proven,
were prospectively enrolled in this study between December 2010
and May 2012 with the assent of the Florence University Hospital.
All the participants signed an informed consent agreement and the
procedures followed in the study were approved by the AOUC
(Azienda Ospedaliero-Universitaria Careggi) Ethical Committee.
The sites and stage of the tumour have been classified according to
the AJCC TNM (Edge et al, 2010). Primary tumour volume was
calculated on the basis of diagnostic imaging, as it is represented by
computer-assisted tomography three-dimensional prospective.
Tumoral and normal tissue specimens were obtained in general
anaesthesia during surgical procedure, under sterile conditions;
peripheral blood samples were taken when patients arrived in the
operating room. Inclusion criteria for enrolment of patients in the
following study were: (1) biopsy-proven HNSCC patients, (2) patients
affected by primary head and neck tumours previously untreated, (3)
patients with no tumour medical history, (4) absence of systemic
metastasis. The patients description is summarised in Table 1.
Outpatient follow-up included clinical examination monthly
during the first year after surgery and every 2 months during the
second year after surgery. A control by computer-assisted
tomography (CAT) was obtained at 1 month postoperatively and
twice a year postoperatively and/or after radiotherapy comple-
mentary treatment, in accordance with recommendations made by
the ethical standards of the Regional Committee on Human
Experimentation.
Reagents. The medium used for T-cell culture was RPMI 1640
(Seromed, Berlin, Germany), supplemented with 2mM L-glutamine,
1% nonessential amino acids, 1% sodium pyruvate, 2" 10# 5M
2-mercaptoethanol (all from Invitrogen, Life Technology,
Thermofischer Scientific Inc, Lafayette, CO, USA) and 10% FBS
HyClone (Gibco Laboratories, Grand Island, NY, USA). Fluoro-
chrome-conjugated anti-CD90, CD31, CD45, CD44, CD73, CD3,
CD45, CD14, CD34, and human epithelial antigen (HEA) were
purchased from BD Biosciences (San Diego, CA, USA). Anti-CD29
and anti-CD105 were obtained from Ancell Corporation, Bayport,
MN, USA. Oil Red O, Alizarin Red S, insulin, IBMX (3-isobutil-
1-metilxantina), indomethacin, dexamethasone were purchased
from Sigma Aldrich, St. Louis, MO, USA.
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Generation of MSCs from BM. Mesenchymal stem cells were
generated from BM aspirates of three healthy donors, recruited
after informed consent, following the procedures of the Interna-
tional Society for Cellular Therapy 2005 (Dominici et al, 2006).
Bone marrow mononuclear cells were separated by density
gradient centrifugation (Lymphoprep; Nycomed, Oslo, Norway)
and cultured in 25-cm2 flask (BD Biosciences) at a concentration of
30" 106 nucleated cells in 5ml of Dulbecco’s modified Eagle’s
medium, GlutaMax I, 10% heat-inactivated adult bovine serum,
penicillin (100Uml# 1), and streptomycin (100 mgml# 1). Cultures
were incubated at 37 1C in a 5% CO2 atmosphere. After 72 h, non-
adherent cells were removed. When 70%–80% adherent cells were
confluent, they were trypsinised (0.25mgml# 1 at 37 1C for 5min),
harvested, and expanded in larger flasks. Out of cells that were
expanded for at least 3 weeks, 499% of them displaying a
homogeneous immunophenotypic pattern were used for the
experiments.
Generation of MSCs from HNSSC. To obtain single-cell suspen-
sions, tumour fragments were first gently digested with collagenase
IV (500Uml# 1, Sigma Aldrich) and then passed through a
stainless-steel mesh (Medimachine; Becton Dickinson, San Diego,
CA, USA). After these procedures, cell suspensions were cultured
as reported in the previous paragraph.
Flow cytometric analysis. Tumour-ASCs immunophenotypic
analysis was performed as detailed elsewhere (Krampera et al,
2006). Briefly, tumour-MSCs were detached using EDTA-buffer,
washed, and resuspended at 106 cells per millilitre. One hundred
microlitres of cell suspension was incubated with the specific mAbs
at þ 4 1C for 30min; cells were then washed and analysed on a
BDLSRII flow cytometer using the Diva software (BD Biosciences).
Tumour-MSCs and BM-MSCs differentiation assay. The differ-
entiation potential of tumour-MSCs and BM-MSCs was assessed
by testing their ability to differentiate into adypocytes and
osteoblasts. Adipocytic differentiation was achieved after a 3-week
culture of MSCs in adipogenic medium composed of DMEM with
high glucose, 10% bovine serum, 1mM dexamethasone, 0.5 mM
3-isobutyl-1-methylaxantine, 10 mgml# 1 insulin, and 100 mM
indomethacin. After 3 weeks, the culture medium was removed
from all cultures and cells were smoothly washed with 2ml of PBS
to not affect the cell monolayer, PBS was then removed and 2ml of
10% formaldehyde were added for 30min at room temperature.
Subsequently, formaldehyde was removed from each well, cells
washed with water, and 2ml of 60% isopropanol were added for
2–5min. Then isopropanol was removed and the cells were stained
with 2ml of Oil Red O (reconstituted in 99% isopropanol) for
5min. After several washes with warm tap water, cells were
counterstained with haematoxylin for 1min, rinsed with tap water
and visualised on a phase contrast microscope. Osteoblastic
differentiation was achieved after a 3-week culture with osteo-
blastic medium containing DMEM high glucose, 2% bovine serum,
10# 7M dexamethasone, 50mgml# 1 ascorbic acid, and 10mM
b-glycerophosphate. The cells were then washed with PBS, fixed
with 10% formaldehyde for 10min, rinsed with PBS, stained with
Alizarin Red (1mgml# 1, dissolved in distilled water) for 3min,
washed few times with tap water and analysed on a phase contrast
microscope. Also specific markers of adipoblasts and osteoblasts
were analysed by real-time quantitative RT–PCR at different time
points during cell differentiation.
Isolation of CD4þ or CD8þ T Cells from PB. Negative
selection of CD4þ or CD8þ T cells from PB of healthy donor
was performed by MACS (Miltenyi Biotec, Bisley, UK; DE, EU), as
described elsewhere (Krampera et al, 2006). The purity of the
negatively selected populations was consistently X97%.
Proliferation assays. Purified CD4þ or CD8þ human T cells
(105 cells) were stimulated with either 105 irradiated (9000 rad)
allogeneic T-cell-depleted PBMCs (MLR – mixed lymphocytes
reaction) plus 1mgml# 1 of anti-CD3 mAb (BD Biosciences);
or 5mgml# 1 anti-CD3 plus 5mgml# 1 anti-CD28 mAb (BD
Biosciences), in the absence or presence of different numbers of
tumour-MSCs (2" 104,104,103,102 per well). Co-culture experiments
were performed in RPMI 1640 medium (Seromed), supplemented as
indicated in the first paragraph. On day 5, cultures were pulsed for
8 h with 0.5mCi (0.0185MBq) of 3H-TdR (Amersham, Little
Chalfont, UK) harvested, and radionuclide uptake was measured
by scintillation counting. Some experiments were conducted in the
presence of the IDO1 inhibitor 1-methyl-L-tryptophan (1, 0.5, or
0.25mM) or in the presence of the COX inhibitor indomethacin
(1, 0.5, 0.25mcM) purchased from Sigma Aldrich.
Cytokine production assay. Anti-CD3 plus anti-CD28-stimulated
CD4þ or CD8þ T cells were co-cultured in the presence or in
the absence of MSCs as described above, culture supernatants were
collected after 72 h to evaluate TNF-a and IFN-g production. The
amounts of cytokines were measured by a commercial ELISA kit
(R&D System) according to the manufacturer’s instructions.
Table 1. Patients characteristics
Patients Gender
Age
(years)
Site of
tumour
TNM
status
Tumour
volume (cc)
Previous
radiotherapy-
chemotherapy
Follow-up
(months)
#1 F 51 Larynx pT3N0M0 12.74 No 25
#2 M 64 Tongue pT1N0M0 0.8736 No 25
#3 M 66 Larynx pT3N2cM0 4.94 No 25
#4 M 71 Larynx pT1N1aM0 0.52 No 24
#5 F 65 Oral cavity floor pT4bN1M0 1.04 No 23
#6 M 76 Oral cavity floor T4bN0M0 22.23 No 21
#7 M 64 Larynx pT2N0M0 0.0364 No 21
#8 M 57 Tonsil pT3N2cM0 15.6 No 20
#9 M 47 Tongue pT2N0M0 6.864 No 15
#10 F 66 Tonsil pT2N2cM0 1.95 No 13
#11 F 66 Larynx pT2N1M0 0.39 No 8
#12 F 65 Larynx pT3N1M0 0.676 No 10
#13 M 60 Larynx pT4aN2bM0 2.184 No 9
8M/5F 62.8±7.8 s.d. 18.4±6.5 s.d.
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Chemotactic assay. BM-MSC or tumour-MSC were stimulated in
the presence of recombinant TNF-a plus IFN-g (10 ngml# 1 and
2 ngml# 1, respectively) to induce chemokines production. After
24 h, culture medium was removed and fresh medium (RPMI
1640) was added for further 24 h. The culture supernatants were
then collected and added to the bottom well of a transwell chamber
(5 mm pore size, 24 wells; Costar, Corning Incorporated, Corning,
NY, USA). Freshly isolated 2.5" 105 CD4þ or CD8þT cells,
obtained from peripheral blood of healthy donors, were resus-
pended in normal culture medium and loaded into the top well.
Cell migration was allowed to occur for 4 h at 37 1C and cells
migrating to the lower chamber were collected and counted by
BD-LSR cytofluorimeter. Cells that migrated in the presence of
medium alone served as a negative control, whereas those
migrating in the presence of CXCL10 (200 ngml# 1) served as
positive control.
Real-time quantitative RT–PCR. Taq-Man RT–PCR was per-
formed, as described elsewhere (Cosmi et al, 2008; Annunziato and
Romagnani, 2010; Murphy and Stockinger, 2010). Primers and
probes used were from Applied Biosystems (Foster City, CA, USA).
Statistical analysis. An unpaired samples t-test was used to assess
the difference of MSCs frequency between tumour and healthy tissue
(Figure 1), between mRNA expression of adipocytes or osteoblasts cell
markers in undifferentiated and in vitro differentiated tumour-MSCs
(Figure 3) and between cell proliferation of polyclonally stimulated T
cells in the absence or in the presence of tumour-MSCs (or BM-MSCs
as control condition, Figure 4, panel A and B). The correlation
between the frequency of CD90-positive cells and tumour volume,
and between CD90-positive cells and CD45þ or CD31þ cells was
evaluated on the basis of R2 and number of subjects (Figure 5).
Po0.05 (two-tailed) was considered statistically significant.
RESULTS
CD90-positive stromal cells are enriched in HNSCC. As first
step, we evaluated the relative proportions of cells belonging to
different cell lineages in HNSCC or healthy tissue derived from the
upper aerodigestive tract. In particular, we generated single-cell
suspensions from specimens derived from 13 different HNSCC-
affected patients. From 6 out of the 13 patients, it was possible to
obtain also control specimens (healthy tissue) derived from the
contralateral of the tumour. Cell suspensions were evaluated by
flow cytometry to establish the frequency of epithelial elements
(HEAþ cells), of stromal cells (CD90þ cells), of endothelial cells
(CD31þ cells), and of leukocytes (CD45þ cells). Debris and dead
cells were excluded from the plot analysis on the basis of physic
parameters, as well as the propidium iodide uptake method. CD31,
together with CD29, CD105, CD73, and CD133 have been
evaluated on eight patients out of 13, depending on the number
of cells recovered from tumoral specimens.
As shown in Figure 1A, the frequency of CD90þ cells were
significantly higher in tumour vs control specimens. Even if
frequencies of HEA and CD31 expressing cells were slightly higher
in tumoral specimens as compared with healthy tissues, the
differences were not statistically significant. The unexpected low
frequency of HEA-positive cells in the tumoral specimens was
related to the high frequency of propidium iodide-positive cells
among them (data not shown).
Adherent stromal cells obtained in vitro from HNSCC share
phenotypic and stemness properties with BM-MSCs from
healthy subjects. We obtained, from 9 out of the 13 patients, a
number of cells that allowed their seeding in plastic flasks, to derive
stromal adherent cells accordingly to the procedures recommended
by the International Society for Cellular Therapy (2005) for the
isolation of MSCs. Two cell cultures out of nine were discarded
because of bacterial contamination; the remaining seven cultures
proliferated in vitro as homogeneous adherent cells populations
resembling the morphology of BM-MSCs. After 3 weeks of culture
(p3–p4), cells were detached, collected, and evaluated by flow
cytometry for the expression of conventionally accepted BM-MSC
cell markers, namely CD44, CD105, CD73, CD90, CD29, CD31,
CD45, CD14, CD34. Moreover, to exclude the presence of
epithelial cells, we assessed these cells also for human epithelial
antigen (HEA) positivity, in as much as the starting cell
suspensions contained also epithelial elements. As shown in
Figure 1B, adherent stromal cells obtained from tumour specimens
shared the same phenotype with control BM-MSCs (obtained from
three different healthy donors). To further exclude the presence of
epithelial elements, we evaluated by real-time quantitative RT–
PCR, all cell cultures for the expression of mRNA for cytokeratin,
and we could confirm the absence of this marker (data not shown).
To study the differentiation potential of tumour-adherent
stromal cells towards osteogenic or lipogenic lineages, we cultured
the cells from the six cultures possessing sufficient numbers of
elements, in the presence of appropriate culture media. In
particular, tumour-adherent stromal cells or BM-MSCs, used as
standard control, were seeded in the presence of adipogenic,
osteogenic, or normal culture medium. After 3 weeks, adherent
cells from the above-mentioned culture conditions were stained
with Oil Red O to evaluate lipogenic differentiation, or with
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Figure 1. CD90þ cells are enriched in HNSCC. (A) The relative
proportions of HEAþ , CD90þ , CD31þ , and CD45þ cells were
assessed by flow cytometry on fresh single-cell suspensions derived
from HNSCC specimens (black columns, n¼ 13 for HEA, CD90, and
CD45; n¼8 for CD31), or control healthy tissue (white columns, n¼ 6).
Columns represent mean values±s.e. of independent experiments.
P-value is calculated comparing tumoral tissue vs healthy tissue.
(B) Tumour-derived stromal cells and control BM-MSCs share the same
immunophenotype. Adherent homogeneous stromal cells obtained
from seven different patients were collected at list after 3 weeks of
culture and assessed by flow cytometry for MSCs markers (black
columns), and compared with control BM-MSCs obtained from three
different healthy donors (white columns). Columns represent mean
values±s.e.
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Alizarin Red, to evaluate osteogenic differentiation. As represented
in Figure 2A, neither BM-MSC, nor tumour-adherent stromal cells,
acquired any positive staining when cultured in normal culture
medium, whereas both kinds of cells were positively stained with
Oil Red O, when cultured in lipogenic medium, or with Alizarin
Red when conditioned by osteogenic medium. To further support
these data, mRNAs for markers highly expressed during adipoblast
or osteoblast differentiation were measured at different time points
of cell culture by real-time quantitative RT–PCR. With regard to
adipoblast differentiation, tumour-adherent stromal cells acquired
a clear mRNA expression for PPAR-g and for FABp4, similar to
that of BM-MSC (Figure 2 panel B). Moreover, when these cells
were cultured in the presence of osteogenic medium, they acquired
a significant upregulation of the mRNAs for the osteoblast’s
markers alkaline phosphatase (ALP), Runt-related transcription
factor 2 (RUNX 2) and osteocalcin (Figure 2 panel C). On the basis
of these results, we named the adherent stromal cells derived from
HNSCC as tumour-MSCs, in analogy to BM-MSCs.
Tumour-MSCs inhibit in vitro cell proliferation and cytokine
production of activated CD4þ and CD8þ T cells. It is well
established that BM-MSCs display immunosuppressive activity
towards various immune system cell types and in particular vs
T cells. We, therefore, wondered if tumour-MSCs, resembling
BM-MSC for phenotypic features and differentiation potential, also
displayed immunoregulatory properties. To assess this point,
we co-cultured polyclonally- (anti-CD3 plus anti-CD28) or
MLR-stimulated allogeneic CD4þ or CD8þ T cells with scalar
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Figure 2. Adherent stromal cells derived from tumours specimens acquires typical adipoblast or osteoblast staining after adequate in vitro
conditioning. (A) Adherent cells derived from HNSCC specimens of six different patients or control BM-MSCs, were cultured in normal culture
medium (CM), in the presence of osteogenic medium (OM) or adipogenic medium (AM) for 21 days. After this period, tumour-derived stromal cells
were stained with haematoxylin and eosin plus Oil Red O or with Alizarin Red, and compared with BM-MSCs to assess their in vitro cell
differentiation. Phase contrast images were obtained by an optic microscope (Axiovert 40C Carl Zeiss) with a "20 magnification. A representative
case out of six is reported (tumour-MSCs) and compared with a representative control case out of three (BM-MSCs). (B, C) Adherent stromal cells
derived from HNSCC specimens acquires typical adipoblast or osteoblast mRNAs after in vitro culture in the presence of appropriate conditioning
medium. mRNA levels for adipoblast or osteoblast markers were evaluated in HNSCC-derived adherent stromal cells (black columns, n¼ 6) or in
BM-MSCs (white columns, n¼3) at the beginning of the experiment (time 0 – T0), after 7 and 21 days of culture in the presence of normal culture
medium (CM), adipogenic medium (AM), or osteogenic medium (OM). B reports mean values±s.e. of the specific mRNAs for the adipose markers
ppar-g and FABp4 at the different time points. C reports the mRNAs mean values±s.e. for the osteogenic markers alkaline phosphatase (ALP),
Runt-related transcription factor 2 (RUNX 2) and osteocalcin. P-values are evaluated for HNSCC-derived adherent stromal cells vs own control
condition (CM) at each time point.
MSCs from HNSCC display immunoregulatory activity BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.15 749
numbers of tumour-MSCs or of BM-MSCs (control cells); both
adherent cells types were seeded in the absence or presence of
stimulated T cells at different MSC/T cells ratios: 1/5, 1/10, 1/100,
and 1/1000. On day 5, lymphocytes were assessed for their ability
to proliferate through the evaluation of 3H-TdR uptake. As shown
in Figure 3A, the addition in cultures of tumour-MSCs significantly
inhibited the proliferation of stimulated T cells in a dose-
dependent fashion. Of note, the immunosuppressive behaviour of
tumour-MSC was comparable to the one of BM-MSCs.
T cells were also evaluated for cytokine production, in
particular, anti-CD3 plus anti-CD28-stimulated CD4þ or
CD8þ T cells were co-cultured in the presence or in the absence
of MSCs as described above, culture supernatants were collected
after 72 h to evaluate TNF-a and IFN-g production. As shown in
Figure 3B, the production of both cytokines was significantly
inhibited by tumour-MSCs in CD4þ and CD8þ T cells,
particularly at the higher MSC/T-cell ratio.
Tumour-MSC inhibits T-cell proliferation via indoelamine 2,3
dioxygenase (IDO) activity. To define the molecular mechanism
at the base of tumour-MSCs immunoregulation, we took advantage
of our previous data regarding the role of the enzyme IDO1 in the
immunoregulatory activity of human BM-MSCs (Krampera et al,
2006) In particular, we repeated the above-mentioned experiments
on the basis of MSC/T-cell co-cultures, in the presence or absence
of the IDO1 inhibitor methyl-L-tryptophan. As shown in
Figure 4A, this compound significantly abrogated the immuno-
regulatory activity of tumour-MSCs, in a dose-dependent fashion,
demonstrating the role of IDO in the molecular mechanism of
immunoregulation of tumour-MSCs. To define the possible
involvement of PGE2, which has been previously shown to have
a role in the inhibitory activity of BM-MSC (Le Blanc et al, 2004),
in the immunosuppressive feature of tumour-MSC, we performed
experiments on the basis of MSC/T-cell co-cultures, in the
presence or absence of the COX inhibitor indomethacin which
impairs PGE2 production. The results showed that blocking of
PGE2 production in tumour-MSC was not able to restore CD4þ
T-cell proliferation (Figure 4B).
Tumour-MSC exert chemotactic activity on T cells. Although
the above-described immunosuppressive mechanism is not contact
dependent, it requires that MSCs and T cells share the same
microenvironment. In a previous study (Krampera et al, 2006), we
found that on stimulation with the inflammatory cytokines IFN-g
and TNF-a, BM-MSC produce CXCL10, a chemokine highly active
on T cells. In the present study, we found that tumour-MSC also
are able to produce CXCL10 under the same experimental
conditions (data not shown). To demonstrate that tumour-MSC
can actively attract T cells, a transwell chemotactic assay was
performed, in which CD4þ or CD8þ T cells were induced to
migrate in response to supernatants obtained from two stimulated
tumour-MSC. As shown in Figure 5, not only recombinant
CXCL10 but also BM-MSC and tumour-MSC supernatants were
able to significantly attract both T-cell subpopulations.
The frequency of CD90-positive stromal cells in HNSCC directly
correlates with tumour size. To investigate the possible role of
tumour-MSCs in the growth of HNSCC tumours, we took
advantage of the data regarding the frequency of CD90þ cells
in tumour specimens; the mesenchymal nature of these cells
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Figure 3. Tumour-MSCs inhibit in vitro cell proliferation and cytokines production by polyclonally stimulated CD4þ and CD8þ T lymphocytes.
(A) Proliferation of polyclonally stimulated (anti-CD3 plus anti-CD28) T lymphocytes was assessed after 5 days of culture on the basis of 3H
thymidine incorporation in the absence (T) or in the presence of tumour-MSCs (black columns) or of BM-MSCs (white columns) as control condition.
Histograms represent mean values±s.e. of six different experiments. P-values are evaluated vs T cells alone. (B) Cytokine production by
polyclonally stimulated T lymphocytes was assessed in supernatants by ELISA, after 3 days of culture in the absence (T) or in the presence of
tumour-MSCs. Histograms represent mean values±s.e. of three different experiments. P-values are evaluated vs T cells alone.
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was confirmed by flow cytometric analysis by evaluating the
co-expression of CD29, CD73, and CD105, in the absence of
CD133, CD45, CD31, CD14, and HEA (data not shown).
In particular, the frequency of CD90þ cells measured in single-cell
suspension freshly derived from tumour specimens, was correlated
with the dimension of neoplasm, as measured by computed
tomography: longitudinal" lateral" transversal diameter (cm)" p/6
(Dethlefsen et al, 1968). As shown in Figure 6, the frequency of
CD90þ cells directly and significantly correlated with tumour
volume. Interestingly the frequency of CD90þ cells inversely
correlated with the frequency of tumour-infiltrating leukocytes
(CD45þ cells). Finally a positive trend in the correlation between
CD90þ cells and endothelial CD31þ cells was observed, but, in this
case, the statistical analysis did not give a significant result, probably
because of the lower number of subjects evaluated for CD31.
DISCUSSION
Mesenchymal stem cells are essential components of tumour
stromal cells, and have a pivotal role in tumour microenvironment,
by modulating tumour growth and development. These cells are
able to become tumour-associated fibroblasts (TAFs), which
contribute to fibrovascular network expansion and tumour
progression (Mishra et al, 2008; Spaeth et al, 2009). Mesenchymal
stem cells are also capable of differentiating into pericytes and
mural cells around tumour blood vessels, thus contributing to the
formation of tumoral vasculature (Rajantie et al, 2004). Mesen-
chymal stem cells are generally believed to reach the tumour from
the bone marrow (Horwitz et al, 2005), in as much as a strong
evidence demonstrates that MSCs home to injury sites in various
pathological conditions, including inflammation, tissue repair, and
neoplasms (Natsu et al, 2004; Rojas et al, 2005; Hall et al, 2007).
During progression and development of tumours, MSCs can be
recruited in large numbers to the tumour site. On the other hand,
it is well known that BM-MSCs exert immunosuppressive activity
on various cells of the immune system (Hu et al, 2013).
In the present study, we hypothesised that MSC or MSC-like
cells present in HNSCC exhibit immunoregulatory activities,
similar to their bone marrow counterpart, favouring tumour
escape, growth, and progression of disease. To assess this issue, we
evaluated, by flow cytometric analysis, the relative proportions of
cells belonging to the stromal/mesenchymal lineage (CD90þ ,
CD29þ , CD105þ , CD73þ , CD31# , CD45# , CD133# , cells),
cells of endothelial origin (CD31þ elements), of epithelial origins
(HEAþ elements), and leukocytes (CD45þ cells). CD90þ
stromal cells were significantly enriched in fresh samples of
tumour tissue compared with healthy tissue derived from the
aerodigestive tract of the same patients, whereas no significant
differences were noticed for the other cell markers. Moreover, we
demonstrated that it was possible to derive from HNSCC,
homogeneous cultures of cell resembling classic BM-MSC in terms
of morphology, immune-phenotype, and differentiation potential.
In particular, stromal cells isolated from tumour samples, showed a
fibroblast-like shape when evaluated by direct microscopy and the
same immunophenotype pattern of BM-MSC as evaluated by flow
cytometry (CD44þ , CD105þ , CD73þ , CD90þ , CD29þ ,
CD31# , CD45# , CD14# , CD34# , HEA# ). The results
demonstrated that adherent cells isolated by tumoral specimens
were homogeneously characterised by the same phenotype of BM-
MSCs obtained from healthy donors. To evaluate the functional
capability of tumour-MSCs to differentiate towards specific
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Figure 4. Indoelamine 2,3 dioxygenase (IDO) activity is on the basis of
tumour-MSCs immunoregulatory activity. (A) Cell proliferation of
polyclonally stimulated CD4þ T cells was assessed as previously
indicated in the absence or in the presence of tumour-MSCs with or
without the IDO1 inhibitor methyl-L-triptophane in scalar doses.
Histograms represent mean values±s.e. of four different experiments.
P-values are evaluated vs T cells alone. (B) Analogous experiments
were conducted in the absence or in the presence of the COX inhibitor
indomethacin in scalar concentration. Histograms represent mean
values±s.e. of four different experiments; P-value was calculated vs
T cells alone and resulted o0.01 at MSC/T-cell ratio 1/5 and 1/10 in
the control condition (medium alone) and also in the presence of the
different concentrations of indomethacin.
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Figure 5. Tumour-MSC actively attract CD4þ and CD8þ T cells.
In vitro chemotaxis of CD4þ or CD8þ T cells was evaluated in
transwell chambers in the presence of normal culture medium (negative
control), in the presence of CXCL10 (positive control), or in the
presence of medium conditioned by tumour-MSC derived from two
different patients (tumour-MSC1 and 2). As further control, the
conditioned medium obtained from BM-MSC also was evaluated.
Histograms represent the mean values±s.e. of triplicates of two
separated experiments.
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stromal cell lineages, we cultured them in the presence of
appropriate differentiating media for osteoblast or adipoblast
differentiation. This functional capability allows us to conclude
that these tumour-derived cells are MSCs and not fibroblasts, and
indeed it is not possible to distinguish MSCs from fibroblasts on
the basis of the immunophenotype alone. After adequate cell
culturing, we were able to demonstrate both osteogenic and
adipogenic cell differentiation either in terms of immunohisto-
chemistry or expression of specific mRNAs, as measured by real-
time quantitative RT–PCR. Thus, we concluded that tumour-MSCs
share morphologic, immunophenotypic, and differentiation fea-
tures with BM-MSCs.
As a second step, we evaluated the in vitro immunoregulatory
properties of tumour-MSCs. To this end, we co-cultured scalar
numbers of tumour-MSCs with anti-CD3 plus anti-CD28# or
MLR-stimulated CD4þ or CD8þ T cells, and then we measured
the proliferative activity of lymphocytes by 3H thymidine uptake
after 5 days of culture. The results of these experiments
demonstrated that tumour-MSCs consistently and significantly
inhibited the in vitro proliferation of CD4þ and of CD8þ T cells,
at the higher MSC/lymphocytes ratios (1/5 and 1/10), in the same
manner as control BM-MSCs. Moreover, we demonstrated that
tumour-MSCs share the main molecular mechanisms of immune
suppression with BM-MSCs, namely the enzymatic activity
of IDO1. As known, this enzyme is induced in human MSCs
by IFN-g produced by T or by NK cells, and is responsible for
the catabolism of the essential amino acid tryptophan, and for the
generation of the toxic compounds kynurenines; these latter are
inhibitory for T-cell proliferation and cytokine production and also
responsible for apoptosis induction. In particular, we showed that
addition in culture of the IDO inhibitor 6-methyl-L-triptophane
abrogated the tumour-MSC inhibitory effect on T-cell prolifera-
tion, whereas the addition of the COX antagonist indomethacin
that have been reported by some researchers to have inhibitory
effects on MSC immunoregulation, had poor effect on BM- and on
tumour-MSCs, at least in our hands. Interestingly tumour-MSCs
resulted were able to attract CD4þ and CD8þ T cells in in vitro
chemotactic assays, supporting the idea that tumour-MSC are able
to actively attract T lymphocytes and then suppress them in terms
of cell proliferation and cytokine production. These data are
consistent with a recent publication where it has been demon-
strated that MSC derived from different tumours are able to attract
in vitro peripheral blood mononuclear cells (Al-toub et al, 2013).
Taken together, these data demonstrate that the in vitro
immunoregulatory activity of tumour-MSC is quantitatively and
qualitatively comparable with that of BM-MSCs. On this basis, we
hypothesised that tumour-MSC also could possess an immuno-
regulatory activity in vivo, as already demonstrated for BM-MSCs
(Bartholomew et al, 2002; Le Blanc et al, 2004; Baron et al, 2010).
To verify this hypothesis, we evaluated the correlation between the
frequency of tumour-MSC present in neoplasm specimens and
the tumour size. We could appreciate a direct and significant
correlation between these two parameters, suggesting a favouring
role of tumour-MSC for neoplasm growth. More interestingly, we
observed an inverse and significant correlation between tumour-
MSCs and the frequencies of leukocytes infiltrating the tumour,
thus suggesting that tumour-MSCs could exert immunoregulatory
activity also in vivo, as already shown in in vitro models, as well as
in mice and in humans with regard to BM-MSC. Our data are in
agreement with the work by Ling et al (2014), that demonstrates
the ability of mice MSC, transfected with human IDO, to strongly
inhibit in vitro cell proliferation of both CD4þ and CD8þ
T lymphocytes. Moreover the positive correlation between CD90þ
cells and tumour size is in keeping with a recent publication by
Kansy et al (2014), where the authors confirm the presence of MSCs
in HNSCC, and find that MSCs in vitro can establish a direct cross-
talk with tumoral cells resulting in MSC activation, cytokines
production, and subsequent tumoral cell growth.
In conclusion, our study demonstrates that in head neck
tumours, the MSC cell population is enriched when compared with
control healthy tissue, and shares with conventional BM-MSCs
both immunophenotype and differentiation potential. Thus, these
cells possess the potential to work as the stromal progenitors at
tumoral level, implicated in the generation of the different cell type
of tumoral connective tissue; in accordance with this concept,
we observed a positive trend, even if not significant, between
CD90þ cells and CD31þ CD45# (endothelial) cells. Interest-
ingly, tumour-MSCs exhibit evidence for immunosuppressive
activity in in vitro models, being able to abrogate cell proliferation
and cytokine production by CD4þ and CD8þ T cells. Notably,
the molecular mechanism on the basis of this immunoregulatory
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Figure 6. Frequency of CD90-positive cells in HNSCC directly
correlates with tumour volume and inversely with leukocyte infiltrate.
(A) The frequency of CD90þ cells present at level of HNSCC fresh
samples, as assessed by flow cytometry on single-cell suspensions, was
correlated with tumour size (longitudinal" lateral" transversal
diameter (cm)" 0.52), n¼ 13. (B) The frequency of CD90þ cells
determined as previously described, was correlated with the frequency
of tumour-infiltrating leukocyte (CD45þ ) n¼13. (C) The frequency of
CD90þ cells was correlated with the frequency of endothelial cells
(CD45#CD31þ cells) n¼8. R2 and P-values are indicated in each panel.
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activity is mainly related to the IDO activity, as already
demonstrated for conventional human BM-MSCs, whose immuno-
suppressive activity in vivo is well documented. These data together
with the observation that the frequency of tumour-MSCs directly
correlates with tumour size and inversely correlates with the
numbers of tumour-infiltrating leucocytes, let us to hypothesize that
tumour-MSCs may favour tumour growth, either directly or
indirectly inhibiting the immune response. However, these data
need to be confirmed on a bigger cohort of patients and the
correlation between the frequency of tumour-MSCs and the clinical
history of the disease need to be monitored for an adequate follow-
up period.
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